Biophan Technologies, Inc. Biophans Patented Innovations Improve Medical Devices 2005 Money Show Michael Weiner, CEO.

Slides:



Advertisements
Similar presentations
Overview of the Keys to Successful Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. Tucson, Arizona October 18, 2001.
Advertisements

AEMK Systems inc. Deltabot for food packaging industry
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
University Industry Collaboration Guven Yalcintas, Ph.D. Vice President Technology Transfer Office The Research Foundation of SUNY Alfred, NY-April 27,
Intellectual Property HEY Trusts New IP Policy and Role of Medipex Will it enable me to turn this…. into.
Gilead’s Tech Transfer Partnerships and IP in India
Cool-Head Device Brain-Saving device by Hypermed, inc
PLAZMA HEATING PRODUCT INDIA G-52 LAWRENCE ROAD,INDUSTRIAL AREA, NEW DELHI
MedTech – An Overview Markets with Great Future Potential Opportunities for Innovation Opportunities for Innovation and Investment Alan Barrell – Chairman.
Technology Commercialization Gerald J. Siuta, Ph.D. President Siuta Consulting, Inc. ( Vice President for Affiliate Members Association.
TAKE Solutions Enabling Business Efficiencies Ram Yeleswarapu President & CEO Analysts Meet Mumbai September 18, 2008.
Shareholders Meeting August 22, 2013 CONFIDENTIAL1.
Biophan Technologies, Inc. Company Overview Michael Weiner, CEO Pharma Finance 2005 Conference June 23, 2005.
Innovative and well established product development company.
Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
Nanotechnology for Medical Devices and Biomaterial Applications Michael Weiner, CEO, Biophan Technologies, Inc. World Nano-Economic Congress (WNEC) Ireland.
Biophan Technologies, Inc. Company Overview Michael Weiner, CEO “Nanotechnology: The Future is Now” Symposium July 29, 2005.
Biophan Technologies, Inc. Company Overview Michael Weiner, CEO Cinapsys Microcap Conference June 29, 2005.
H MRI Marker Active MRI Stents & Vena Cava Filter -brief introduction- Andreas Melzer University of Applied Sciences Gelsenkirchen Institute for Innovative.
The Medical Device Industry in Southern New England’s I-91 Corridor Potential for growth September, 2004 and the role of BEACON Joseph D. Bronzino, Ph.
Biophan Technologies, Inc. Company Overview and Update The Wall Street Analyst Forum – 16 th Annual Analyst Conference March 2, 2005 Michael Weiner, CEO.
Behringhauser Str Castrop-Rauxel GERMANY Tel. +49 – – Fax +49 – –
LogNet Information Technologies PLC May Innovative software company of customer experience solutions for multiple verticals Core products include.
Sourcing Agreement Between
Magnetic Resonance Imaging Mary Holleboom ENGR 302 May 7, 2002.
Presented by the UCLA Undergraduate Investment Society.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
DMD Conference McNamara Alumni Center April 10, 2013 Bin He, Ph.D. Director, Institute for Engineering in Medicine.
CyteVice Alvin Dabhi Aditya Sai 5/1/2013 “Discover the discovery”
STAR Park Forum September Who We Are Through its global network, Thermon provides highly engineered thermal solutions, known as heat tracing, for.
Randy Tremper and Dean Peterson Los Alamos National Laboratory Los Alamos, New Mexico Superconductivity Technology Center Overview Develop Energy Efficient.
Biophan Technologies, Inc. Investor Presentation Michael Weiner, CEO August 2006.
Constructing the “Price” of the Technology in IP Licensing Negotiations Sub Regional Training Program on IP Valuation Maribor November 5 to 7, 2012.
Business Acumen Training October 8, 2014 JOHNSON & JOHNSON Confidential, unpublished property of Cigna. Do not duplicate or distribute. Use and distribution.
Biophan Technologies, Inc. Investor Presentation July 2006.
Biophan Technologies, Inc. Investor Presentation Michael Weiner, CEO July 10, 2006.
Best Strategies for a Small Company Dealing with CMOs: What to do when Money is NOT a Motivator Steve Pondell 29 Nov, 2006.
Biophan Technologies, Inc. Company Overview and Update Michael Weiner, CEO Stephens 2005 Nanotechnology Investors Conference April 6, 2005.
Drug Delivery and Generic Medicine The Challenge ahead; Choose where to play. MENA as an Industry Model Mohammad Refaat Khattab Cairo University; Egypt.
Questcor Pharmaceuticals, Inc
Biophan Technologies, Inc. OTC: BIPH. 2 Cautionary Statement Certain statements included in this presentation may constitute forward-looking statements.
0 15 July The SKF Group Half-year results 2008 Tom Johnstone, President and CEO.
Coronary Stents  A stent is a support device for permanent expansion of blood vessel to restore blood flow.  Implantation is done with X-ray guidance.
HSC 6636: Pharmaceuticals & Medical Technology 1 Dr. Lawrence West, Health Management and Informatics Department, University of Central Florida
SELECTED IDEAS FROM FROM IDEAS TO ASSETS (CHAPTER 5 AND 15) BY JONAS HELLER Managing IP Financial Assets and Analyzing Financial Growth.
FDA’s Public Workshop: Innovative Systems for Delivery of Drugs and Biologics: Scientific, Clinical, and Regulatory Challenges Paul Goldfarb, MD, FACS.
ICU MEDICAL, INC.. 1 FORWARD LOOKING INFORMATION Any statement concerning Management’s expectation with respect to future results is a forward looking.
THE PROBLEM: CURRENT CONTINUOUS GLUCOSE MONITORS (CGM) ARE INVASIVE Continuous glucose monitoring is critical for some diabetics and very advantageous.
Pan Boricua must decide whether to expand, stay in markets where they are weak, and/or expand to other markets in the United States.
Biophan Technologies, Inc. Jeffrey L. Helfer, Vice President of Engineering ISMRM Workshop on MRI Safety November 6, 2005.
1 INSPIRED DRIVEN COMMITTED VISION PRESENTATION APRIL 2015 BY DESIGN AORTIC.
The Role of New Markets Advisors in Healthcare Case Study in Pharma.
AktieTorgets investerarfrukost 17 september 2015 David Westberg, CEO.
Advanced Drug Delivery John Lanzafame Biophan Technologies, Inc.
Targeted Drug Therapeutics An overview of our technologies and their potential 505(b)(2) applications Sino-American Regulatory Consulting Alliance Yongtian.
1 Alternative Mechanism for Technology Transfer: Licensing YoungJun Kim Department of Economics The George Washington University
SCIENCE & INNOVATION TUTORIAL
Foresight Science & Technology, Inc.
Universities and the Commercial World
Global Active Implantable Medical Devices Market to Witness 8% CAGR during 2017 – 2023.
MEDICAL DEVICE COATING MARKET FORECAST 2018 TO 2023 Industry Survey, Growth, Competitive Landscape and Forecasts to 2023 PREPARED BY Market Research Future.
9.4 Product Quality Control
Biophan Technologies, Inc. Investor Presentation July 2006
Acquisition Boston Scientific – Guidant
Biophan Technologies, Inc. Company Overview
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Low Power Wide Area Network.
NASA Kennedy Space Center
TE Connectivity Medical.
Presentation transcript:

Biophan Technologies, Inc. Biophans Patented Innovations Improve Medical Devices 2005 Money Show Michael Weiner, CEO

Biophan Technologies, Inc.(OTCBB: BIPH) MEDICAL INNOVATION The United States and most modern countries place a very high value on medical innovation Once approved in the market, a medical innovation can generate significant wealth for the inventors and for the shareholders of the company(s) bringing the innovation to market Over the past fifty years, medical innovations have changed the quality of life immensely, and made many large, and small, fortunes

Biophan Technologies, Inc.(OTCBB: BIPH) PATENTS AND MONEY U.S. Patents are one of the most potentially valuable financial instruments in the world Once issued, they provide the exclusive right to make, use, or sell, the invention within the United States of America The claims are where the true value lies One claim can be worth as much as $1 billion (Polaroid vs. Kodak)

Biophan Technologies, Inc.(OTCBB: BIPH) Enhancements Once a product is on the market, another series of innovations and enhancements to the core device can create significant additional wealth Some examples: demand pacing enhancement over pacemakers The implantable defibrillator enhancement Communicating pacemakers Implantable insulin pumps Hundreds more, worth BILLION$

Biophan Technologies, Inc.(OTCBB: BIPH) BIOPHANs BUSINESS Founded with pacemaker inventor Wilson Greatbatch, to make pacemakers safe for use with MRI Expanded to include $12 billion worth of medical devices that ship with one problem, or another Problems had not been solved by the medical device manufacturers Finding, and patenting, a solution, would help patients, and help manufacturers offer a better device That was the founding idea behind Biophan Without a strong U.S. Patent system, there would be little incentive to invest money on solutions like this

Biophan Technologies, Inc.(OTCBB: BIPH) INNOVATIONS IN INNOVATION Biophan invests shareholder dollars… To discover, patent, and implement Valuable enhancements to multi-billion dollar device markets Where the resulting innovation can make a major shift in marketshare, among major industry players, in major industries Biophan holds 36 issued US patents, and has 72 more pending; plus many international patents

Biophan Technologies, Inc.(OTCBB: BIPH) Management Stu MacDonald, VP R&D – formerly VP R&D at J&J division, with a 400 person organization Jeff Helfer, VP Engineering – formerly Dir. Of Engineering at the same J&J division John Lanzafame, President, Nanolution Division – former President STS Biopolymers, acquired by Angiotech (ANPI) Robert Wood, VP Finance, Treasurer, Secretary, and CFO – CPA in public and private firms Michael Friebe, Ph.D., MRI Scientist & Entrepreneur Andreas Melzer, MD, renowned medical innovator

Biophan Technologies, Inc.(OTCBB: BIPH) Biophans Mission Enable over $12 billion worth of medical devices shipping annually safe for use with MRI, and imageable. Many are not: Guidewires, catheters, endoscopes, biopsy needles Pacemakers, defibrillators, neurostimulators, drug pumps (safety issues, also imaging issues), pain control devices Stents, embolism clips, aneurysm clips, artificial hips, knees, most other orthopedics Bring other innovations for competitive advantage to biomedical device and pharmaceutical companies.

Biophan Technologies, Inc.(OTCBB: BIPH) Biophans Solutions MRI Safety: (many products contraindicated) RF filter from Johns Hopkins (heating) Anti-Antenna lead design (heating & induced voltages) MRI Safe non-magnetic motor Nanomagnetic particle technologies Minimize image artifacts Makes catheters, guidewires, stents, etc visible under MRI Contrast agents Drug Delivery

Biophan Technologies, Inc.(OTCBB: BIPH) PROTECTED, PROTECTED! Technologies covered by 114 U.S. Patents 36 ISSUED 72 pending or allowed Owned by Biophan or licensed exclusively to Biophan for the medical market Plus many International patents

MRI Device Imaging SE coronal image of 3 aluminum wires (1/32). Wire (3) is uncoated. 123 Biophans thin-film nanomagnetic particle coating technology provides a controllable, magnetic signal capable of creating an image of the coated device. #3 is uncoated.

Biophan Technologies, Inc.(OTCBB: BIPH) Making Stents Imageable Seeing blockage of stents has required an invasive procedure Stents imageable under MRI would be competitively advantaged Nanoset has a nanomagnetic particle, thin film coating AMRIS, now Biophan-Europe, has a retrofit solution Both solutions are PATENTED!

Biophan Technologies, Inc.(OTCBB: BIPH) 1.5 Tesla MRI Artifacts of Current Stents Expanded Stents Original size Crimped Stents Cobalt 316L stainless steel With existing stent technology, no useful images can be obtained from within common stents using MRI.

Imaging of In-Stent Blood Clots Using Biophan Resonator Technology 1 Tesla Philips NT, head coil, TR=300ms, TE=6ms, FA=40°, transversal Cross Sectional Schematic of Stent with blood clot Video Biophans technology enables imaging of the blood clot within the stent Resonant StentBlood Clot

Biophan Technologies, Inc.(OTCBB: BIPH) Implications Impact the $5+ billion stent market Help manufacturers make pacemakers, defibrillators, and neurostimulators safe, and imageable – competitive advantage to our licensees Make guidewires, catheters, endoscopes, and biopsy needles safe and image compatible Opens the field of interventional medicine under MRI (currently only X-Ray/Fluoroscopy)

Biophan Technologies, Inc.(OTCBB: BIPH) Biothermal Battery Goal: To provide a long-lived electrical power system for implanted medical devices Powered by body heat differential. Batteries are a $500 million market, sell for $100 to $225 each in the pacemaker, defibrillator and drug pump markets Sold to same customers who need MRI safety Nanomaterials brings this capability within striking distance. We hold issued and pending patents

Biophan Technologies, Inc.(OTCBB: BIPH) Agreement with NASA Announced on August 17 th a deal with NASA Ames Research Center for Nanotechnology to jointly develop the biothermal battery NASA wants technology for their long duration manned MARS mission for biosensing and miniature therapeutic devices Biophan gets commercial rights to jointly developed and NASA developed technology Nanotechnology and materials science advances makes the biothermal battery possible

Non-Magnetic MRI-Safe and Imageable Greater efficiency Enables precision 20 nm movements Ideal for drug pumps, cryogenic applications, implantables Biophan holds worldwide medical distribution rights, + equity

Biophan Technologies, Inc.(OTCBB: BIPH) Substrate Polymer Coating Nanomagnetic layer Controlled Magnetic Field Drug bound to NMP carrier Controlled Magnetic Field A Controlled Magnetic Field B Particle type A Drug A Particle type B Drug B Surface Elution on Demand

Biophan Technologies, Inc.(OTCBB: BIPH) Reloading Drug Eluting Coatings Substrate Polymer Coating Concentration Gradient Controlled Magnetic Field Drug Molecules Drug bound to NMP carrier Nanomagnetic layer

Biophan Technologies, Inc.(OTCBB: BIPH) Guided Drug Delivery Solid tumor Apply magnetic field to concentrate particles Modulate field to release drug from particles Inject NMPs IV, NMP will circulate through the blood stream Other options for targeting: 1 - Direct injection into tumor site 2 - Coating NMP with antibodies to target tumor

Biophan Technologies, Inc.(OTCBB: BIPH) Markets Medical devices (safe &/or image): $12 billion Battery: $500 million Contrast Agents: $800 million Drug Pumps: $1 billion Drug Delivery: $40 billion Once a deal is underway, patents and annuity streams can last a long time; We anticipate money on signing, in development; plus milestones, royalties, high margin components

Biophan Technologies, Inc.(OTCBB: BIPH) Business Model Offering our customers competitive advantage Through proprietary solutions that can gain marketshare for them FDA approval is pursued by the customer Marketing and distribution of the final device is their responsibility We sell high margin components and develop annuities for our shareholders

Biophan Technologies, Inc.(OTCBB: BIPH) Relationship With Boston Scientific Joint development agreement, originally entered into November, 2003 Recently moved to second and third phase, and has expanded to multiple products Reached agreement on term sheet, working on final contract phase

Biophan Technologies, Inc.(OTCBB: BIPH) Summary Financial Information Share Price ( ): $ Week High: $ Week Low: $0.46 Shares Outstanding: 74 million Float: 58 million Market Cap: $176 million Average Daily Volume: 1,218,772

Biophan Technologies, Inc.(OTCBB: BIPH) BIOPHAN (OTCBB: BIPH)

Biophan Technologies, Inc.(OTCBB: BIPH) Biophan (OTC: BIPH) We dont make medical devices; We make them safe, and imageable, for MRI And other competitive advantages for our customers Four of our six technologies are based on nanotechnology